Personalized

Regulatory Innovation for a More Personalized Era of Medicine

Pharma's Almanac

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac

Clinical Evidence

Rethinking Clinical Evidence Requirements in Rare Diseases

David Alvaro, Ph.D.

Pharma's Almanac

Protein Misfolding

Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Supply Chain

Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Nice Insight

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

Alzheimer Therapies

Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

David Alvaro, Ph.D.

Pharma's Almanac

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Molecular Barcodes

Molecular Tags, DNA Barcodes, and the Future of Pharmaceutical Supply Chain Authentication

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lyophilized vs. Liquid Drug Formulations: Which Formulation Strategy Is Better?

Nice Insight

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Oligo Analytics

Impurities, Sequence Fidelity, and Structural Variants in Nucleic Acid Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

Gut-Brain Axis

The Gut–Brain Axis and the Future of Microbiome-Directed Mental Health Strategies

David Alvaro, Ph.D.

Pharma's Almanac